MedTrace Logo

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

NCT00609193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2015-12-07

No results posted yet for this study

Summary

The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium. Both of these medicines are FDA-approved to treat mania in adults and lithium is also FDA approved in children; quetiapine is commonly used in children with mania, but is not FDA approved for this indication in this age group.

Conditions

Interventions

DRUG

lithium

standard clinical care

DRUG

quetiapine

standard clinical care

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Stephen M Strakowski, MD · University of Cincinnati

Eligibility

Min Age
12 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2015-06-30
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00609193 on ClinicalTrials.gov